Deerfield partner Jonathan Leff issued a serious warning to the biotech industry during a policy panel at the BIO CEO & Investor Conference Feb. 14, declaring that sweeping changes to FDA’s drug approval standards under a new administration and a new commissioner could have “disastrous consequences” for biotech investment.
“FDA as we know it has been about regulating the efficacy as well as the safety of drugs,” Leff said....



